# A Study of 2 Different Formulations of Blosozumab (LY2541546) in Post Menopausal Women

> **NCT02337387** · PHASE1 · TERMINATED · sponsor: **Eli Lilly and Company** · enrollment: 28 (actual)

## Conditions studied

- Osteoporosis, Postmenopausal

## Interventions

- **BIOLOGICAL:** Blosozumab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02337387
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-01
- **Primary completion:** 2015-03
- **Final completion:** 2015-03
- **Target enrollment:** 28 (ACTUAL)
- **Why stopped:** Protocol stopping criteria (safety) were met.
- **Last updated:** 2019-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02337387

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02337387, "A Study of 2 Different Formulations of Blosozumab (LY2541546) in Post Menopausal Women". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02337387. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*